0
0
CAPE COAST, GHANA – Smokers face a drastically increased risk of developing severe eye conditions that can lead to vision loss, including age-related macular degeneration (AMD), cataracts, and glaucoma, according to a comprehensive new analysis published recently. The findings highlight the urgent need for smokers to quit, as researchers found that even a past history of smoking elevates the risk for certain ocular disorders.
The study, a “meta-meta-analysis” reviewing existing research, revealed alarming statistics. Current smokers were found to have up to a 12-fold higher risk (Odds Ratio [OR] 11.93) for age-related macular degeneration compared to non-smokers. Even those who had smoked at any point in their lives showed a significantly increased likelihood of developing AMD (OR 7.09).
The risks extend to other common eye diseases. Current smokers were found to have approximately triple the risk (OR 3.07) for primary open-angle glaucoma, a leading cause of irreversible blindness. Notably, past smokers maintained a similarly high risk (OR 2.64). Furthermore, the analysis showed current smokers were nearly four times more likely (OR 4.15) to develop cataracts, a clouding of the eye’s lens. Individuals with any history of smoking faced an almost sixfold increased risk (OR 5.96) for cataracts.
This extensive review was conducted by researchers led by Randy Asiamah from the University of Cape Coast, Ghana. They systematically searched major scientific databases (PubMed, Scopus, Web of Science) through December 2024, identifying 12 relevant meta-analyses that encompassed prospective cohort, cross-sectional, and case-control studies. These analyses compared the risk of eye diseases – specifically AMD, cataracts, primary open-angle glaucoma, dry eye disease, and toxic amblyopia – among current, former, and lifetime smokers versus non-smokers.
The researchers emphasized the significance of their findings for public health. “Understanding the relationship between smoking and these ocular conditions is crucial, as smoking is a modifiable risk factor that could be targeted to reduce the prevalence and possible progression of these conditions,” they stated in their report, published online on April 16, 2025, in the European Journal of Ophthalmology.
While the findings paint a stark picture, the study authors acknowledged some limitations. They noted potential overlap between the included meta-analyses, which could introduce a slight risk of skewed reporting. Additionally, there was significant variation (heterogeneity) in the populations studied within the primary research papers included in the original meta-analyses.
The study received no external funding, and the authors declared no conflicts of interest.
Disclaimer: This news article is based on information provided from a specific study published in the European Journal of Ophthalmology. It is intended for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
